Changes in hospitalizations and emergency department respiratory viral diagnosis trends before and during the COVID-19 pandemic in Ontario, Canada.


Journal

PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081

Informations de publication

Date de publication:
2023
Historique:
received: 22 12 2022
accepted: 05 06 2023
medline: 19 6 2023
pubmed: 16 6 2023
entrez: 16 6 2023
Statut: epublish

Résumé

Population-level surveillance systems have demonstrated reduced transmission of non-SARS-CoV-2 respiratory viruses during the COVID-19 pandemic. In this study, we examined whether this reduction translated to reduced hospital admissions and emergency department (ED) visits associated with influenza, respiratory syncytial virus (RSV), human metapneumovirus, human parainfluenza virus, adenovirus, rhinovirus/enterovirus, and common cold coronavirus in Ontario. Hospital admissions were identified from the Discharge Abstract Database and exclude elective surgical admissions and non-emergency medical admissions (January 2017-March 2022). Emergency department (ED) visits were identified from the National Ambulatory Care Reporting System. International Classification of Diseases (ICD-10) codes were used to classify hospital visits by virus type (January 2017-May 2022). At the onset of the COVID-19 pandemic, hospitalizations for all viruses were reduced to near-trough levels. Hospitalizations and ED visits for influenza (9,127/year and 23,061/year, respectively) were nearly absent throughout the pandemic (two influenza seasons; April 2020-March 2022). Hospitalizations and ED visits for RSV (3,765/year and 736/year, respectively) were absent for the first RSV season during the pandemic, but returned for the 2021/2022 season. This resurgence of hospitalizations for RSV occurred earlier in the season than expected, was more likely among younger infants (age ≤6 months), more likely among older children (aged 6.1-24 months), and less likely to comprise of patients residing in higher areas of ethnic diversity (p<0.0001). During the COVID-19 pandemic, there was a reduced the burden of other respiratory infections on patients and hospitals. The epidemiology of respiratory viruses in the 2022/23 season remains to be seen.

Identifiants

pubmed: 37327212
doi: 10.1371/journal.pone.0287395
pii: PONE-D-22-35031
pmc: PMC10275476
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e0287395

Informations de copyright

Copyright: © 2023 Habbous et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Lancet Reg Health Am. 2021 Sep;1:100015
pubmed: 34386788
BMC Infect Dis. 2018 Oct 29;18(1):540
pubmed: 30373527
Can J Public Health. 2012 Apr 30;103(8 Suppl 2):S12-6
pubmed: 23618065
Pediatr Pulmonol. 2021 Oct;56(10):3106-3109
pubmed: 34273135
PLoS One. 2021 Jan 7;16(1):e0244746
pubmed: 33411792
J Infect. 2022 May;84(5):722-746
pubmed: 35123959
J Glob Health. 2021 Mar 01;11:05007
pubmed: 33791096
J Infect Dis. 2022 Dec 28;227(1):83-86
pubmed: 36315855
Can Commun Dis Rep. 2021 Mar 31;47(3):132-138
pubmed: 34012336
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296672
Influenza Other Respir Viruses. 2022 Sep;16(5):926-936
pubmed: 35733362
Medicine (Baltimore). 2022 Aug 12;101(32):e29439
pubmed: 35960102
J Infect Dis. 2022 Mar 15;225(6):957-964
pubmed: 35030633
J Infect Dis. 2022 Dec 13;226(12):2047-2049
pubmed: 36052654
Ann Thorac Med. 2023 Apr-Jun;18(2):70-78
pubmed: 37323374
Med Microbiol Immunol. 2021 Dec;210(5-6):277-282
pubmed: 34604931
CMAJ. 2021 Mar 22;193(12):E410-E418
pubmed: 33568436
Engineering (Beijing). 2023 Feb;21:195-202
pubmed: 35127196
Nat Commun. 2022 May 24;13(1):2884
pubmed: 35610217
Viruses. 2022 Sep 28;14(10):
pubmed: 36298690
Nat Rev Microbiol. 2023 Mar;21(3):195-210
pubmed: 36253478
Infect Control Hosp Epidemiol. 2023 Jan;44(1):62-67
pubmed: 35177161
Int J Infect Dis. 2022 Jul;120:205-209
pubmed: 35472530
Nat Med. 2020 May;26(5):676-680
pubmed: 32371934
CMAJ. 2021 Jul 26;193(29):E1140-E1141
pubmed: 34312169
Emerg Themes Epidemiol. 2021 Oct 21;18(1):15
pubmed: 34674730
Microbes Environ. 2015;30(2):140-4
pubmed: 25843687
Annu Rev Virol. 2020 Sep 29;7(1):83-101
pubmed: 32196426
Lancet Reg Health Am. 2022 Mar;7:100132
pubmed: 35291567
J Infect. 2022 Jan;84(1):40-47
pubmed: 34757137
Can Commun Dis Rep. 2022 Jan 26;48(1):39-45
pubmed: 35273468
Nat Rev Microbiol. 2021 Aug;19(8):528-545
pubmed: 33753932
Immun Inflamm Dis. 2022 Aug;10(8):e672
pubmed: 35894708
N Engl J Med. 2022 Jun 23;386(25):2377-2386
pubmed: 35731653
Euro Surveill. 2021 Oct;26(40):
pubmed: 34622760
Infection. 2022 Dec;50(6):1587-1590
pubmed: 35904753
Epidemics. 2022 Sep;40:100614
pubmed: 35901639
J Orthop Res. 2016 Feb;34(2):197-204
pubmed: 26228250
Euro Surveill. 2021 Jul;26(29):
pubmed: 34296673
Influenza Other Respir Viruses. 2022 Jan;16(1):72-78
pubmed: 34427056
Health Policy. 2021 Oct;125(10):1291-1296
pubmed: 34420801
Proc Natl Acad Sci U S A. 2019 Dec 26;116(52):27142-27150
pubmed: 31843887

Auteurs

Steven Habbous (S)

Ontario Health (Strategic Analytics), Toronto, Ontario, Canada.
Epidemiology & Biostatistics, Western University, London, Ontario, Canada.

Susy Hota (S)

Department of Medicine, Division of Infectious Diseases, University Health Network, Toronto, Ontario, Canada.

Vanessa G Allen (VG)

Ontario Health (Strategic Analytics), Toronto, Ontario, Canada.
Department of Medicine, Division of Infectious Diseases, University Health Network, Toronto, Ontario, Canada.
Department of Microbiology, Sinai Health/ University Health Network, Toronto, Ontario, Canada.

Michele Henry (M)

Ontario Health (Strategic Analytics), Toronto, Ontario, Canada.

Erik Hellsten (E)

Ontario Health (Strategic Analytics), Toronto, Ontario, Canada.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH